These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19134008)

  • 1. Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue.
    Yasen M; Mizushima H; Mogushi K; Obulhasim G; Miyaguchi K; Inoue K; Nakahara I; Ohta T; Aihara A; Tanaka S; Arii S; Tanaka H
    Cancer Sci; 2009 Mar; 100(3):472-80. PubMed ID: 19134008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC.
    Lin ZZ; Jeng YM; Hu FC; Pan HW; Tsao HW; Lai PL; Lee PH; Cheng AL; Hsu HC
    BMC Cancer; 2010 Aug; 10():461. PubMed ID: 20799978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of phosphatidylinositol 4-kinase type IIIα is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma.
    Ilboudo A; Nault JC; Dubois-Pot-Schneider H; Corlu A; Zucman-Rossi J; Samson M; Le Seyec J
    BMC Cancer; 2014 Jan; 14():7. PubMed ID: 24393405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High NEK2 Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy.
    Wubetu GY; Morine Y; Teraoku H; Yoshikawa M; Ishikawa D; Yamada S; Ikemoto T; Saito YU; Imura S; Shimada M
    Anticancer Res; 2016 Feb; 36(2):757-62. PubMed ID: 26851035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of activated Cdc42-associated kinase1 (Ack1) predicts tumor recurrence and poor survival in human hepatocellular carcinoma.
    Wang B; Xu T; Liu J; Zang S; Gao L; Huang A
    Pathol Res Pract; 2014 Dec; 210(12):787-92. PubMed ID: 25445114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma.
    Tovuu LO; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Arakawa Y; Mori H; Hanaoka J; Kanamoto M; Sugimoto K; Saito Y; Yamada S; Asanoma M; Shimada M
    Int J Clin Oncol; 2014 Aug; 19(4):622-8. PubMed ID: 23893130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatments: in association or alone, their role and their future perspectives: novel molecular-targeted therapy for hepatocellular carcinoma.
    Tanaka S; Arii S
    J Hepatobiliary Pancreat Sci; 2010 Jul; 17(4):413-9. PubMed ID: 19941009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of KIF1B mRNA in hepatocellular carcinoma tissues correlates with poor prognosis.
    Yang SZ; Wang JT; Yu WW; Liu Q; Wu YF; Chen SG
    World J Gastroenterol; 2015 Jul; 21(27):8418-24. PubMed ID: 26217094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low CADM2 expression predicts high recurrence risk of hepatocellular carcinoma patients after hepatectomy.
    Yang S; Yan HL; Tao QF; Yuan SX; Tang GN; Yang Y; Wang LL; Zhang YL; Sun SH; Zhou WP
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):109-16. PubMed ID: 24240726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
    Wang YY; Qi LN; Zhong JH; Qin HG; Ye JZ; Lu SD; Ma L; Xiang BD; Li LQ; You XM
    Sci Rep; 2017 Feb; 7():42199. PubMed ID: 28181486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy.
    Wang ZS; Wu LQ; Yi X; Geng C; Li YJ; Yao RY
    BMC Cancer; 2013 Jun; 13():306. PubMed ID: 23800357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboxypeptidase E is a prediction marker for tumor recurrence in early-stage hepatocellular carcinoma.
    Huang SF; Wu HD; Chen YT; Murthy SR; Chiu YT; Chang Y; Chang IC; Yang X; Loh YP
    Tumour Biol; 2016 Jul; 37(7):9745-53. PubMed ID: 26803519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression and amplification of Aurora-A in hepatocellular carcinoma.
    Jeng YM; Peng SY; Lin CY; Hsu HC
    Clin Cancer Res; 2004 Mar; 10(6):2065-71. PubMed ID: 15041727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma.
    Kuo CC; Shih YL; Su HY; Yan MD; Hsieh CB; Liu CY; Huang WT; Yu MH; Lin YW
    World J Gastroenterol; 2015 Apr; 21(13):3960-9. PubMed ID: 25852282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MST4 promotes hepatocellular carcinoma epithelial-mesenchymal transition and metastasis via activation of the p-ERK pathway.
    Lin ZH; Wang L; Zhang JB; Liu Y; Li XQ; Guo L; Zhang B; Zhu WW; Ye QH
    Int J Oncol; 2014 Aug; 45(2):629-40. PubMed ID: 24859810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and functional significance of the erythropoietin receptor in hepatocellular carcinoma.
    Shin M; Hong D; Zhang Z; Kim YM; Lee W; Joh JW; Kim SJ
    HPB (Oxford); 2013 Dec; 15(12):965-75. PubMed ID: 23496059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis.
    Wang XJ; Li FF; Zhang YJ; Jiang M; Ren WH
    Cancer Biomark; 2020; 29(3):307-315. PubMed ID: 32716348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.